Clinical Trials Browser

INDUSTRY × Neoplasms × Solutions × Clear all

NCT01976741 2021-05-06

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Phase 1 Completed

168 enrolled 59 charts

GenitourinaryHead & NeckThoracic

Adenocarcinoma of Lung, Urinary Bladder Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

NCT04675021 2021-01-26

Absolute Bioavailability and ADME Study of Savolitinib in Healthy Male Subjects

Phase 1 Completed

Neoplasms